Viewing nowMantiini 10 mg (Memantine Hydrochloride)
Memantine Hydrochloride 10mg
Tablet · Prescription medication
Withus Pharmaceutical Co., Ltd.

MFDS item code 201904395 · Approved 2019.06.27 · Insurance code 660703260
Treatment of moderate to severe Alzheimer's disease
This medication is used for the treatment of moderate to severe Alzheimer's disease.
Administer this drug orally once daily at the same time each day. If necessary, it may be administered twice daily. This drug may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. First week (days 1-7): Administer 5mg once daily for 7 days. Second week (days 8-14): Administer 10mg once daily for 7 days. Third week (days 15-21): Administer 15mg once daily for 7 days. From the fourth week onward: Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Elderly patients: Based on clinical data, the recommended dose in patients aged 65 years and older is 20mg once daily. 3. Patients with renal impairment: No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this drug.
This medication should not be used by patients with a known hypersensitivity to its components or with severe liver or kidney impairment. It should be used with caution in patients with epilepsy or those with a history of seizures, or in patients who have a predisposition to seizures. Additionally, it should not be co-administered with NMDA antagonists such as amantadine, ketamine, or dextromethorphan, as this may increase the risk of adverse effects. Patients with factors that can change urine acidity (pH), such as sudden changes in diet or specific urinary tract infections, should be closely monitored. Due to insufficient clinical data, it should be used cautiously in patients with recent myocardial infarction, congestive heart failure, or uncontrolled hypertension. While taking this medication, watch for symptoms such as dizziness, headache, constipation, drowsiness, and hypertension, as these side effects may occur. Central nervous system adverse reactions such as psychiatric confusion, hallucinations, and psychotic responses have also been reported, so if any abnormal symptoms appear, consult a healthcare professional immediately. This medication can interact with other drugs, so if the patient is taking NMDA antagonists, dopamine agonists, anticholinergic drugs, antipsychotic medications, skeletal muscle relaxants, or anticoagulants, they must consult with a doctor or pharmacist. Women who are pregnant or may become pregnant should carefully consider the potential risk to the fetus before using this medication, and nursing mothers are advised to discontinue breastfeeding as this medication may be passed into breast milk. The safety and efficacy of this medication in children and adolescents under 18 years of age have not been established, so it is not recommended for use in this age group. In case of overdose, symptoms such as confusion, drowsiness, dizziness, agitation, hallucinations, gait disturbances, vomiting, and diarrhea may occur. In such cases, general treatment such as gastric lavage or activated charcoal should be conducted as there is no specific antidote. Care should be taken while driving or operating machinery during this medication; especially in Alzheimer's disease patients whose reaction times may be slowed. Finally, this medication should be stored out of the reach of children, and transferring it to another container can compromise the quality of the medication, so caution is advised.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture from entering. It is best kept at room temperature between 1°C and 30°C, avoiding very hot or cold locations.
Pale yellow to yellow oval film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 10mg
Tablet · Prescription medication
Withus Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.